After Local Therapy for Esophageal Cancer, Should We Continue to Survey Patients and, If So, Why and How?

Restricted access

Jaffer A. Ajani, MD, an internationally recognized expert on gastrointestinal cancers, is Professor of Gastrointestinal Medical Oncology at MD Anderson Cancer Center and Chair of the NCCN Clinical Practice Guidelines in Oncology for Esophageal and Gastric Cancers. He has participated over the past 20 years in numerous trials using innovative combined modality therapies for localized gastric and esophageal cancers, and some of his work has led to the development of strategies of preoperative therapy for resectable upper gastrointestinal cancers.

His current research focus is on developing programs to research the molecular markers for progression of Barrett’s metaplasia to adenocarcinoma. These research efforts involve multi-institutional collaboration with investigators at the University of Chicago, University of Pennsylvania, Mayo Clinic, and Yonsei University, in Seoul, Korea.

In addition to his work with NCCN, Dr. Ajani participates actively in the International Society of Gastrointestinal Oncology is the editor of the Society’s journal, Gastrointestinal Oncology Research.

The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.

  • 1.

    Allum WH, Stenning SP, Bancewicz J. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:50625027.

    • Search Google Scholar
    • Export Citation
  • 2.

    Ajani JA, Barthel JS, Bentrem DJ. NCCN Clinical Practice Guidelines in Oncology for esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011;9:830887.

    • Search Google Scholar
    • Export Citation
  • 3.

    van Hagen P, Hulshof MC, van Lanschot JJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:20742084.

    • Search Google Scholar
    • Export Citation
  • 4.

    Cooper JS, Guo MD, Herskovic A. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:16231627.

    • Search Google Scholar
    • Export Citation
  • 5.

    Dorth JA, Pura JA, Palta M. Patterns of recurrence after trimodality therapy for esophageal cancer. Cancer 2014;120:20992105.

  • 6.

    Sudo K, Taketa T, Correa AM. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 2013;31:43064310.

    • Search Google Scholar
    • Export Citation
  • 7.

    Sudo K, Xiao L, Wadhwa R. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014;32:34003405.

    • Search Google Scholar
    • Export Citation
  • 8.

    Lou F, Sima CS, Adusumilli PS. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol 2013;8:15581562.

  • 9.

    Taketa T, Sudo K, Correa AM. Post chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw, in press.

    • Search Google Scholar
    • Export Citation
  • 10.

    Shiozaki H, Sudo K, Xiao L. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology 2014;86:336339.

    • Search Google Scholar
    • Export Citation
  • 11.

    Oppedijk V, van der Gaast A, van Lanschot JJ. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol 2014;32:385391.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 31 21 0
PDF Downloads 13 11 0
EPUB Downloads 0 0 0